CytoSorbents, Inc.

337 articles with CytoSorbents, Inc.

• CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

  6/1/2021

  Terri Anne Powers, IRC, experienced financial and communications professional, to strengthen and expand relationships with the investment and broader stakeholder community by building best-in-class investor relations and corporate communications function

• CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

  5/27/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb®  blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021.

• CytoSorb® Registered and Commercially Available in Singapore

  5/25/2021

  CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical

• CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit

  5/19/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb®  blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will present an overview of the Company's progress and outlook at the UBS Global Conference

• CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

  5/11/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb ® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a contract

• U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

  4/19/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care leader whose flagship E.U. approved CytoSorb ® blood purification technology is intended to treat deadly conditions in critically-ill and cardiac surgery patients, announces that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its investigational device exemption application

• CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

  3/29/2021

  CytoSorbents Corporation announces the lease of its new global headquarters in Princeton, NJ. On March, 26, 2021, the company entered into a new agreement with National Business Parks to lease approximately 48,500 square feet located at 305 College Road East at Princeton Forrestal Village in Princeton, New Jersey.

• CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/12/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb®  blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Oppenheimer 31 st Annual Healthcare Conference.

• B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

  3/2/2021

  Joint marketing of CytoSorb® with B. Braun's newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.

• CytoSorbents to Report Fiscal 2020 Operating and Financial Results

  3/1/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report fiscal 2020 financial results on Tuesday, March 9, 2021 at 4:45PM EST . 

• CytoSorbents to Present at the Cowen 41st Annual Health Care Conference

  2/24/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb®  blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Cowen 41 st Annual Health Care Conference.

• CytoSorbents 2021: Leadership and Growth in the "New Normal"

  2/18/2021

  CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Chief Executive Officer, Dr. Phillip Chan.

• CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference

  2/16/2021

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb®  blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation in the 10 th Annual SVB Leerink Global Healthcare Conferen

• CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory Affairs

  1/21/2021

  David D. Cox, PhD, MBA, seasoned regulatory professional, tapped to lead CytoSorbents global regulatory initiatives and U.S. FDA approval of CytoSorb

• CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing

  1/11/2021

  Seasoned sales veteran from Medtronic tasked to build and lead U.S. commercialization infrastructure as CytoSorbents sells CytoSorb under U.S. FDA Emergency Use Authorization for COVID-19 and leverages FDA Breakthrough Designation for potential future U.S. approval.

• Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

  1/4/2021

  CytoSorb now immediately commercially available throughout North America for use in COVID-19 patients, and in a total of 67 countries worldwide

• CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank

  12/10/2020

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb®  blood purification technology to treat deadly inflammation in critically i

• CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CARE

  12/2/2020

  CytoSorbents Corporation announces the launch of its international fundraising campaign to raise $100,000 to benefit the global, not-for-profit humanitarian organization, CARE USA.

• CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients

  11/25/2020

  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb®  blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the publication of the largest case series using CytoSorb in critically ill

• CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference

  11/12/2020

  CytoSorbents Corporation announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 and meet with investors in 1x1 meetings throughout the day.